Welwyn Garden City, UK – 9th January 2013 – Cresset Group, innovative provider of chemistry software and services, announces that ProMining Therapeutics Ltd has chosen to license Spark for assistance in its hit-to-lead optimization efforts. Spark is Cresset’s desktop bioisostere software tool which is used by medicinal and computational chemists for drug design.
“Spark is an exciting and powerful way of generating novel and diverse structures. We are delighted that ProMining, an early-stage biopharmaceutical research and development company, has chosen to work with Spark for the development of small molecule drugs,” says Dr David Bardsley, Cresset’s Sales Director.
Dr Boaz Inbal, CTO at ProMining Therapeutics Ltd. says, “We are excited about using Spark for hit-to-lead optimization purposes in our oncology project. We believe that Spark will guide us through several optimization challenges. As a result, we will be able to better understand the behavior of several chemical groups in the context of our hit scaffold and to test some required replacement hypotheses.”
Dr Bardsley adds, “Cresset’s software works at the meeting point of chemistry and biology, giving chemists a way of understanding their molecules in terms of biological activity. Cresset’s technology and services are providing companies with the right information, wherever they sit in the drug design workflow.”